CO6241107A2 - Acidos carboxilicos sustituidos con fenilaminobenzoxazol metodos para su produccion y su uso como medicamento - Google Patents

Acidos carboxilicos sustituidos con fenilaminobenzoxazol metodos para su produccion y su uso como medicamento

Info

Publication number
CO6241107A2
CO6241107A2 CO08116211A CO08116211A CO6241107A2 CO 6241107 A2 CO6241107 A2 CO 6241107A2 CO 08116211 A CO08116211 A CO 08116211A CO 08116211 A CO08116211 A CO 08116211A CO 6241107 A2 CO6241107 A2 CO 6241107A2
Authority
CO
Colombia
Prior art keywords
alkylene
cycloalkyl
alkenylene
alkyl
phenyl
Prior art date
Application number
CO08116211A
Other languages
English (en)
Inventor
Elisabeth Defossa
Markus Follmann
Thomas Klabunde
Viktoria Drosou
Gerhard Hessler
Siegfried Stengelin
Guido Haschke
Andreas Herling
Stefan Bartoschenk
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CO6241107A2 publication Critical patent/CO6241107A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a ácidos carboxílicos sustituidos con fenilaminobenzoxazol y a sus sales fisiológicamente toleradas. La invención se refiere también a compuestos de la fórmula (I)en la que R1, R2, R6, R7, R8, R9, R10, m y X tienen los significados establecidos, y a sus sales fisiológicamente toleradas. Dichos compuestos son adecuados para el tratamiento de la diabetes. 1.- Un compuesto de la fórmula Ien la que los significados son R1 H o alquilo (C1-C6); R6, R7, R8, R9, R10, independientemente unos de otros, H, F, CI, Br, CN, CF3, OH, OCF3, OCHF2, SCH3, SCF3, fenilo, O-fenilo, COOH, COO-alquilo (C1-C6), CO-alquilo (C1-C6), alquilo (C1-C6), O-alquilo (C1-C6), OBn, SO3H, SO2NR3R4, NR3R4 o SO2-N-piperidinilo, donde alquilo y fenilo pueden estar sustituidos una o más veces con R2, y donde en cada caso dos de los radicales R6, R7, R8, R9, R10, en posición adyacente en el anillo fenilo pueden formar juntos un radical -O-CH2-O-, -O-(CH2)2-O- o -CH=CH-CH=CH-; m 0, 1, 2 ó 3; X enlace, alquileno (C2-C10), cicloalquilo (C3-C12), alquilen (C1-C8)-cicloalquil (C3-C12)-alquileno (C1-C8), alquilen (C1-C8)-cicloalquilo (C3-C12), cicloalquil (C3-C12)-alquileno (C1-C8), alquenilen (C2-C8)-cicloalquil (C3-C12)-alquileno (C1-C8), alquilen (C1-C8)-cicloalquil (C3-C12)-alquenileno (C2-C8), alquenilen (C2-C8)-cicloalquilo (C3-C12), cicloalquil (C3-C12)- alquenileno (C2-C8), alquenileno (C2-C10) o alquinileno (C2-C10), en los que alquileno, cicloalquilo, alquenileno y alquinileno pueden estar sustituidos una o más veces con R5; R2 OH, F, CI, Br, CN, OCH3, OCF3, CH3, CF3, ...
CO08116211A 2006-05-11 2008-10-30 Acidos carboxilicos sustituidos con fenilaminobenzoxazol metodos para su produccion y su uso como medicamento CO6241107A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006021878A DE102006021878A1 (de) 2006-05-11 2006-05-11 Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
CO6241107A2 true CO6241107A2 (es) 2011-01-20

Family

ID=38371048

Family Applications (1)

Application Number Title Priority Date Filing Date
CO08116211A CO6241107A2 (es) 2006-05-11 2008-10-30 Acidos carboxilicos sustituidos con fenilaminobenzoxazol metodos para su produccion y su uso como medicamento

Country Status (31)

Country Link
US (2) US20090149519A1 (es)
EP (1) EP2024347B1 (es)
JP (1) JP2009536629A (es)
KR (1) KR20090006846A (es)
CN (1) CN101437805B (es)
AR (1) AR060990A1 (es)
AU (1) AU2007250213B2 (es)
BR (1) BRPI0711448A2 (es)
CA (1) CA2651660A1 (es)
CO (1) CO6241107A2 (es)
CY (1) CY1113177T1 (es)
DE (1) DE102006021878A1 (es)
DK (1) DK2024347T3 (es)
ES (1) ES2391203T3 (es)
HK (1) HK1131978A1 (es)
HR (1) HRP20120829T1 (es)
IL (1) IL195179A0 (es)
MA (1) MA30402B1 (es)
MX (1) MX2008014102A (es)
MY (1) MY148258A (es)
NO (1) NO20085068L (es)
NZ (1) NZ572692A (es)
PL (1) PL2024347T3 (es)
PT (1) PT2024347E (es)
RS (1) RS52450B (es)
RU (1) RU2434003C2 (es)
SI (1) SI2024347T1 (es)
TW (1) TW200812987A (es)
UY (1) UY30338A1 (es)
WO (1) WO2007131622A1 (es)
ZA (1) ZA200808490B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
AU2006291234A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
EP2139843B1 (en) 2007-04-16 2013-12-25 Amgen, Inc Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR20100090249A (ko) 2007-10-10 2010-08-13 암젠 인크 치환된 비페닐 grp40 조절제
WO2009145829A1 (en) * 2008-04-01 2009-12-03 University Of Massachusetts Type iii secretion inhibitors, analogs and uses thereof
JP2011515341A (ja) 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011140190A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tetrazolones as inhibitors of fatty acid synthase
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション PPARδアゴニストの胎児再プログラミング用途
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013039140A1 (ja) * 2011-09-14 2013-03-21 第一三共株式会社 縮合へテロ環誘導体
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4234030A3 (en) 2018-07-13 2023-10-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
AU2020206036A1 (en) 2019-01-11 2021-08-05 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1491863A (en) * 1973-10-23 1977-11-16 Lilly Industries Ltd 2,5-or 2,6-disubstituted benzoxazoles
US4025637A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
EP0664792B1 (en) * 1992-10-14 2000-01-05 Merck & Co. Inc. Fibrinogen receptor antagonists
ES2201452T3 (es) * 1997-03-14 2004-03-16 Vertex Pharmaceuticals Incorporated Inhibidores de la enzima impdh.
EP1133484A2 (en) * 1998-07-23 2001-09-19 AstraZeneca AB Heterocyclic derivatives and their use as integrin inhibitors
DE60027700T2 (de) * 1999-02-16 2007-05-03 Aventis Pharma Ltd., West Malling Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden
GB0001346D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
WO2002036553A2 (en) * 2000-11-04 2002-05-10 Aventis Pharma Limited Substituted alkanoic acids
IL156064A0 (en) * 2000-12-28 2003-12-23 Daiichi Seiyaku Co Vla-4 inhibitors
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd 2−アリールアミノベンゾオキサゾール誘導体

Also Published As

Publication number Publication date
HK1131978A1 (en) 2010-02-12
JP2009536629A (ja) 2009-10-15
EP2024347B1 (de) 2012-08-01
US20090149519A1 (en) 2009-06-11
EP2024347A1 (de) 2009-02-18
IL195179A0 (en) 2009-08-03
PT2024347E (pt) 2012-10-09
NZ572692A (en) 2011-03-31
SI2024347T1 (sl) 2012-11-30
US20130303578A1 (en) 2013-11-14
NO20085068L (no) 2009-02-04
AR060990A1 (es) 2008-07-30
WO2007131622A1 (de) 2007-11-22
CA2651660A1 (en) 2007-11-22
KR20090006846A (ko) 2009-01-15
AU2007250213A1 (en) 2007-11-22
CN101437805B (zh) 2012-05-30
RU2008148838A (ru) 2010-06-20
US8748465B2 (en) 2014-06-10
PL2024347T3 (pl) 2013-01-31
UY30338A1 (es) 2008-01-02
MA30402B1 (fr) 2009-05-04
DK2024347T3 (da) 2012-10-29
MY148258A (en) 2013-03-29
AU2007250213B2 (en) 2013-04-11
MX2008014102A (es) 2008-11-14
HRP20120829T1 (hr) 2012-11-30
ES2391203T3 (es) 2012-11-22
TW200812987A (en) 2008-03-16
RS52450B (en) 2013-02-28
CN101437805A (zh) 2009-05-20
DE102006021878A1 (de) 2007-11-15
BRPI0711448A2 (pt) 2011-11-08
ZA200808490B (en) 2009-10-28
RU2434003C2 (ru) 2011-11-20
CY1113177T1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
CO6241107A2 (es) Acidos carboxilicos sustituidos con fenilaminobenzoxazol metodos para su produccion y su uso como medicamento
AR068479A1 (es) (carboxilalquilenfenil) feniloxamidas, procedimiento para su preparacion y una coomposicion farmaceutica
AR109033A2 (es) Derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, productos farmacéuticos que comprenden estos compuestos y su uso
ES2486267T3 (es) 2-(Fenil 2-fluoro-substituido)-6-amino-5-cloro-4-pirimidinacarboxilatos y su uso como herbicidas
ES2621140T3 (es) Compuestos ácido acilamino y preparaciones alimenticias que los contienen
CO6260061A2 (es) (ciclopropilfenil)feniloxamidas metodo para su produccion y su uso como medicamento
AR067779A1 (es) Profarmacos dipeptoides y su uso
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
DOP2010000040A (es) Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparación, su aplicación como medicamentos, composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met
AR049883A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos
ECSP099781A (es) Novedosos compuestos que son inhibidores de erk
ECSP088858A (es) Uso de bifenilamidas de ácido arilcarboxílico para el tratamiento de semillas
AR086773A1 (es) Un derivado de cinamida sustituida, el metodo para su preparacion y el uso del mismo
CO6341635A2 (es) Analogos de buprenorfina
CY1117449T1 (el) Φαινυλιουχα ν-ακυλο παραγωγα αμινων και αμινοξεων, μεθοδοι για την παραγωγη αυτων, μια φαρμακευτικη συνθεση και η χρηση αυτων
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
AR061973A1 (es) Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos
AR069961A1 (es) Derivados de (aza)indol sustituidos en la posicion 5 utiles en el tratamiento de la inflamacion y el dolor, composiciones farmaceuticas que los comprenden, proceso de preparacion de los mismos y compuestos intermediarios.
UY30787A1 (es) "inhibidores benzoimidazolicos de trpv1"
AR061377A1 (es) Derivados diazeniodiolatos, procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos en patologias cardiovasculares.
AR054747A1 (es) Compuestos de indanil-piperazina un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CO6280480A2 (es) Ciclopentanos sustituidos que tienen actividad prostaglandina
AR053989A1 (es) Compuestos espiro-hidantoina sustituidos con piridilo. composiciones farmaceuticas y procesos de obtencion.

Legal Events

Date Code Title Description
FC Application refused